VEGFA and pancreatic neoplasm: Adjuvant applications of the exogenous VEFGR inhibitor cediranib after radiotherapy restored tumor inhibition, and studies have shown that using angiogenesis inhibitors to target the VEGF pathway or knocking out the VEGF gene in mouse models with pancreatic cancer or glioblastoma has anti-cancer therapeutic effects by reducing the tumor volume and prolonging survival, but the two actions change tumor phenotypes and enhance tumor invasion and metastasis [26–28].